NCT05988918 2026-03-06
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
Clinical Trials
12 trialsNCT06784752 2026-03-06
NETTER-3
Novartis
Phase 3 Recruiting
NCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT06441331 2025-12-17
KinLET
ITM Solucin GmbH
Phase 1 Recruiting
NCT05636618 2025-11-24
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting
NCT06256705 2025-09-22
OPERANDI-NET
Assistance Publique - Hôpitaux de Paris
Phase NA Recruiting
NCT04609592 2025-09-09
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
Phase 1 Recruiting
NCT05997056 2024-07-16
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Aadi Bioscience, Inc.
Phase 2 Recruiting
NCT04893785 2024-06-18
CABOTEM
National Cancer Institute, Naples
Phase 2 Recruiting
NCT05701241 2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4 Recruiting
NCT05359146 2024-04-19
Beta plus
University Hospital, Basel, Switzerland
Phase EARLY_PHASE1 Recruiting